In a significant development for India’s fight against COVID-19, the World Health Organization (WHO) has granted an Emergency Use Listing (EUL) to Corbevax, the protein subunit vaccine developed by Hyderabad-based pharmaceutical company Biological E Limited. This approval paves the way for wider global access to the vaccine, bolstering international vaccination efforts and offering a safe and effective tool for tackling the pandemic.
Highlights:
- Vaccine: Corbevax, developed by Biological E Limited, India
- Approval: Emergency Use Listing (EUL) granted by the World Health Organization (WHO)
- Significance: Wider global access to the vaccine, boosting international vaccination efforts
- Advantages: Protein subunit vaccine, considered safe and effective
- Increased vaccine availability, enhanced protection against COVID-19
Corbevax, developed by Biological E Limited, India
Corbevaz, India’s COVID-19 vaccine is now granted an emergency use listing by the WHO ( World Health Organisation). Corbewax is a recombinant protein sub-unit, developed from a component of a spike protein on the virus’s surface, this helps the body to build immunity against the virus and is manufactured by the pharmaceutical firm “Biological E Limited “ Situated in INDIA. Corbevaz has the Receptor Binding Domain as an antigen. It is available for consumption only in India for authorized dealers only. Mahima Datla, Managing Director of Biological E Ltd said: “We are pleased with the WHO Emergency Use Listing (EUL) because it would help us use the platform to continue developing COVID-19 vaccines as and when it starts impacting public health. We are confident that this endorsement from WHO will bolster our global fight against COVID-19.”
Approval
The WHO’s EUL signifies that Corbevax has met rigorous international standards for safety, efficacy, and quality. This thorough evaluation process included reviewing data from clinical trials involving thousands of participants. The EUL initially covers adults aged 18 and above, with potential for future expansion to younger age groups as further data becomes available.
Advantages of Corbevax
Corbevax utilizes a protein subunit platform, which involves injecting specific viral proteins instead of the entire weakened or inactive virus. This technology is considered safe and effective, often with fewer side effects compared to other vaccine types. Additionally, Corbevax offers advantages in terms of production and storage, making it a potentially valuable tool for low- and middle-income countries.
The WHO’s EUL for Corbevax is a significant step forward in the global fight against COVID-19. It increases vaccine availability, particularly in regions facing challenges due to supply chain disruptions or cost limitations. Corbevax can contribute to increased vaccination rates, ultimately decreasing transmission and reducing the burden of the pandemic. This development highlights India’s growing prowess in vaccine manufacturing and its commitment to global health initiatives. Corbevax’s EUL represents a crucial milestone in India’s fight against COVID-19 and signifies its contribution to international efforts in tackling the pandemic. The availability of safe and effective vaccines like Corbevax offers hope for a future with greater control over the virus and ultimately, a return to normalcy.
